Author: Redaktion

Our Competencies
- R&D
  
  Committed to delivering future-proof, non-invasive delivery technologies.
  
  more
- Process Development
  
  Investing in your future from scale-up to commercialisation and market launch.
  
  more
- Manufacturing
  
  Your requirements are in safe hands.
  
  more
- CDMO
  
  Total, global team – local contract development and manufacturing.
  
  more
- Skin Lab
  
  In vitro permeation Studies. Expertise so real, it’s palpable.
  
  more
Our Technologies
- TTS
  
  Transdermal therapeutic systems that actively improve outcomes for all.
  
  more
- OTF
  
  Oral thin film technologies – the ideal dose for fast delivery.
  
  more
- MAP
  
  Micro Array Patches – The game changer microneedle technology.
  
  more
- OBDS
  
  The way to deliver large volume and highly viscous formulations, at home.
  
  more
- TOPS
  
  Powerful Topical Patch. Fast Pain Relief, Maximum Comfort
  
  more
- NDD
  
  Nasal drug delivery a patient-friendly pathway
  
  more
Our Company
- Our Purpose
  
  Realising value for partners and better outcomes for patients.
  
  More
- Our Team
  
  Meet the people behind the technology.
  
  more
- Locations
  
  Our locations around the world.
  
  more
Insights
- White Paper
  
  Incisive thought leadership on non-invasive drug delivery.
  
  more
- Webcasts
  
  Our expertise brought to life.
  
  more
- Visit our Blog
  
  Touching every part of the skin.
  
  more
News & Events
- News & PR
  
  Keep to up to date with LTS around the world.
  
  more
- Upcoming Events
  
  Where we can meet up.
  
  more
Sustainability

About Redaktion

This author has not yet filled in any details.
So far Redaktion has created 194 blog entries.

Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinson’s Disease

Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinson’s Disease

March 12, 2018|Press Releases|

Initial results of the market analysis indicate there is a substantial market for AP-CD/LD to potentially serve hundreds of thousands of patients suffering with Parkinson's Disease.